|
LANDMARK CROHN'S DISEASE STUDY by Warwick Selby, June 2007, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D
Flawed Australian CD Study Does Not End MAP Controversy Judith E. Lipton, David P. Barash November 2007 Although the paper by Selby et al1 appears legitimate in its empirical reporting, its conclusions go far beyond its data. No attempt was made to culture or do polymerase chain reaction testing for MAP, either before or after treatment, so no conclusion can be drawn about the effect of their protocol on putative Mycobacterium avium paratuberculosis (MAP) infection. The MAP hypothesis of Crohn’s disease is not tested by this study, nor resolved in anything except the author’s assertions
Australian Crohn’s Antibiotic Study Opens New Horizons/Laura Gitlina, James Bieseckerb November 2007 The recently reported trial by Selby et al, “Two year combination antibiotic therapy with Clarithromycin, Rifabutin and Clofazimine for Crohn’s Disease”1 and the accompanying editorial refer to the controversial topic of Crohn’s disease causation by an infectious agent. In this letter, we address 3 important aspects that may have given careful readers concern
The Australian Antibiotic Trial in Crohn’s Disease: Alternative Conclusions From the Same Study J. Todd Kuenstner November 2007 I wish to comment on the recent article by Warwick Selby and others entitled, “Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazamine for Crohn’s disease
Importance of the Australian Crohn’s Disease Antibiotic Study William Chamberlin November 2007 The article by Warwick Selby, “Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease”1 and the accompanying commentary2 are well written and worth reading carefully. They contain important data and commentary. Unfortunately, despite data supporting the positive impact of properly chosen antibiotics in treating Crohn’s disease (CD) patients, the authors emphasize the negative. The authors report the data accurately, but their interpretations need to be challenged.
Myoconda® – A Combination Antibiotic Therapy for the Treatment of Crohn’s Disease a chronic inflammatory disease of the gastrointestinal tract. The disease most commonly affects the lower small intestine and the large intestine. Symptoms of Crohn’s Disease include abdominal pain, diarrhoea, fever and weight loss. In severe cases, the intestine can become blocked or obstructed, requiring surgery. Young patients with Crohn’s Disease may also suffer growth retardation. Patients suffering Crohn’s Disease are conventionally treated with drugs aimed at reducing inflammation and other associated symptoms. The cause of Crohn’s Disease is unknown, thus the standard treatments aim to treat symptoms rather than the cause of the disease. The bacterium Mycobacterium avium paratuberculosis (MAP) is the lead candidate as an infectious cause of Crohn’s Disease. By targeting the MAP infection, Myoconda® is designed to address the possible source of the disease, rather than attempting to merely alleviate its symptoms. Myoconda®, the Company’s therapy for the treatment of Crohn’s Disease is a combination of three registered antibiotics - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. Myoconda® presents these three compounds in a specific patented combination. Myoconda® is based on the proposition that Crohn’s Disease is caused by infection. Prof. Borody has long been at the forefront of this approach, which is gaining increasing acceptance among gastrointestinal specialists worldwide. Prof. Borody has published significant data demonstrating that patients treated with Myoconda®’s antibiotic combination experience long-term remission of clinical symptoms and inflammation, some for up to nine years. Gastroenterology
University of Liverpool Scientists find how bacteria in cows milk may cause Crohn's disease Liverpool, UK - 10 December 2007: Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea. The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli bacteria found in the body. E.coli is known to be present within Crohn’s disease tissue in increased numbers.
Centre eyes data on bowel disease Sat Jul 28 2007 By Dr. Charles Bernstein The role of Escherichia coli in inflammatory bowel disease Jonathan M Rhodes |
FOUNDERS: Diane and Michael Fagen |